FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160304872> ?p ?o ?g. }

• W3160304872 endingPage "2226" @default.
• W3160304872 startingPage "2219" @default.
• W3160304872 abstract "Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans. Despite several emerging vaccines, there remains no verifiable therapeutic targeted specifically to the virus. Here we present a highly effective small interfering RNA (siRNA) therapeutic against SARS-CoV-2 infection using a novel lipid nanoparticle (LNP) delivery system. Multiple siRNAs targeting highly conserved regions of the SARS-CoV-2 virus were screened, and three candidate siRNAs emerged that effectively inhibit the virus by greater than 90% either alone or in combination with one another. We simultaneously developed and screened two novel LNP formulations for the delivery of these candidate siRNA therapeutics to the lungs, an organ that incurs immense damage during SARS-CoV-2 infection. Encapsulation of siRNAs in these LNPs followed by in vivo injection demonstrated robust repression of virus in the lungs and a pronounced survival advantage to the treated mice. Our LNP-siRNA approaches are scalable and can be administered upon the first sign of SARS-CoV-2 infection in humans. We suggest that an siRNA-LNP therapeutic approach could prove highly useful in treating COVID-19 disease as an adjunctive therapy to current vaccine strategies. Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans. Despite several emerging vaccines, there remains no verifiable therapeutic targeted specifically to the virus. Here we present a highly effective small interfering RNA (siRNA) therapeutic against SARS-CoV-2 infection using a novel lipid nanoparticle (LNP) delivery system. Multiple siRNAs targeting highly conserved regions of the SARS-CoV-2 virus were screened, and three candidate siRNAs emerged that effectively inhibit the virus by greater than 90% either alone or in combination with one another. We simultaneously developed and screened two novel LNP formulations for the delivery of these candidate siRNA therapeutics to the lungs, an organ that incurs immense damage during SARS-CoV-2 infection. Encapsulation of siRNAs in these LNPs followed by in vivo injection demonstrated robust repression of virus in the lungs and a pronounced survival advantage to the treated mice. Our LNP-siRNA approaches are scalable and can be administered upon the first sign of SARS-CoV-2 infection in humans. We suggest that an siRNA-LNP therapeutic approach could prove highly useful in treating COVID-19 disease as an adjunctive therapy to current vaccine strategies." @default.
• W3160304872 created "2021-05-24" @default.
• W3160304872 creator A5000727450 @default.
• W3160304872 creator A5000861370 @default.
• W3160304872 creator A5002875613 @default.
• W3160304872 creator A5011086438 @default.
• W3160304872 creator A5027583111 @default.
• W3160304872 creator A5031114729 @default.
• W3160304872 creator A5031147068 @default.
• W3160304872 creator A5034209514 @default.
• W3160304872 creator A5043947319 @default.
• W3160304872 creator A5050689797 @default.
• W3160304872 creator A5059001271 @default.
• W3160304872 creator A5070178730 @default.
• W3160304872 creator A5070422302 @default.
• W3160304872 creator A5081113455 @default.
• W3160304872 creator A5088005102 @default.
• W3160304872 date "2021-07-01" @default.
• W3160304872 modified "2023-10-17" @default.
• W3160304872 title "A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19" @default.
• W3160304872 cites W1520518044 @default.
• W3160304872 cites W1966929320 @default.
• W3160304872 cites W2005508597 @default.
• W3160304872 cites W2006231275 @default.
• W3160304872 cites W2011962754 @default.
• W3160304872 cites W2019431237 @default.
• W3160304872 cites W2043343078 @default.
• W3160304872 cites W2058332691 @default.
• W3160304872 cites W2073858684 @default.
• W3160304872 cites W2089084676 @default.
• W3160304872 cites W2090085157 @default.
• W3160304872 cites W2105617522 @default.
• W3160304872 cites W2126020016 @default.
• W3160304872 cites W2126746295 @default.
• W3160304872 cites W2140091023 @default.
• W3160304872 cites W2157717331 @default.
• W3160304872 cites W2170585717 @default.
• W3160304872 cites W2604179978 @default.
• W3160304872 cites W2610356532 @default.
• W3160304872 cites W2903444830 @default.
• W3160304872 cites W2949380898 @default.
• W3160304872 cites W3011568661 @default.
• W3160304872 cites W3015140168 @default.
• W3160304872 cites W3017680297 @default.
• W3160304872 cites W3024057275 @default.
• W3160304872 cites W3027630905 @default.
• W3160304872 cites W3087615546 @default.
• W3160304872 cites W3092136311 @default.
• W3160304872 cites W3096064145 @default.
• W3160304872 cites W3128627243 @default.
• W3160304872 cites W3133782701 @default.
• W3160304872 doi "https://doi.org/10.1016/j.ymthe.2021.05.004" @default.
• W3160304872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8118699" @default.
• W3160304872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33992805" @default.
• W3160304872 hasPublicationYear "2021" @default.
• W3160304872 type Work @default.
• W3160304872 sameAs 3160304872 @default.
• W3160304872 citedByCount "87" @default.
• W3160304872 countsByYear W31603048722021 @default.
• W3160304872 countsByYear W31603048722022 @default.
• W3160304872 countsByYear W31603048722023 @default.
• W3160304872 crossrefType "journal-article" @default.
• W3160304872 hasAuthorship W3160304872A5000727450 @default.
• W3160304872 hasAuthorship W3160304872A5000861370 @default.
• W3160304872 hasAuthorship W3160304872A5002875613 @default.
• W3160304872 hasAuthorship W3160304872A5011086438 @default.
• W3160304872 hasAuthorship W3160304872A5027583111 @default.
• W3160304872 hasAuthorship W3160304872A5031114729 @default.
• W3160304872 hasAuthorship W3160304872A5031147068 @default.
• W3160304872 hasAuthorship W3160304872A5034209514 @default.
• W3160304872 hasAuthorship W3160304872A5043947319 @default.
• W3160304872 hasAuthorship W3160304872A5050689797 @default.
• W3160304872 hasAuthorship W3160304872A5059001271 @default.
• W3160304872 hasAuthorship W3160304872A5070178730 @default.
• W3160304872 hasAuthorship W3160304872A5070422302 @default.
• W3160304872 hasAuthorship W3160304872A5081113455 @default.
• W3160304872 hasAuthorship W3160304872A5088005102 @default.
• W3160304872 hasBestOaLocation W31603048721 @default.
• W3160304872 hasConcept C104317684 @default.
• W3160304872 hasConcept C119056186 @default.
• W3160304872 hasConcept C142724271 @default.
• W3160304872 hasConcept C159047783 @default.
• W3160304872 hasConcept C166703698 @default.
• W3160304872 hasConcept C203014093 @default.
• W3160304872 hasConcept C22615655 @default.
• W3160304872 hasConcept C2522874641 @default.
• W3160304872 hasConcept C2777648638 @default.
• W3160304872 hasConcept C2779134260 @default.
• W3160304872 hasConcept C3008058167 @default.
• W3160304872 hasConcept C524204448 @default.
• W3160304872 hasConcept C55493867 @default.
• W3160304872 hasConcept C67705224 @default.
• W3160304872 hasConcept C71924100 @default.
• W3160304872 hasConcept C86803240 @default.
• W3160304872 hasConceptScore W3160304872C104317684 @default.
• W3160304872 hasConceptScore W3160304872C119056186 @default.
• W3160304872 hasConceptScore W3160304872C142724271 @default.
• W3160304872 hasConceptScore W3160304872C159047783 @default.

• next